Phase I study of intravenous TZT-1027 (T) and carboplatin (C), administered on Day 1 (T and C) and Day 8 (T) every three weeks in patients (pts) with advanced solid tumors

Sarah P. Blagden, W.P. Steward, Alastair Greystoke et al.|Journal of Clinical Oncology|2005

Cited by 3